Clinical Trials
167 trialsNCT05387928 2026-05-08
A Study of KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1 Completed
NCT05549804 2026-05-08
A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1 Completed
NCT03317743 2026-04-17
Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors
Idience Co., Ltd.
Phase 1 Completed
NCT06242691 2026-03-06
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT05800964 2026-02-17
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT06556108 2026-01-20
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
Xinqiao Hospital of Chongqing
Phase 1/2 Completed
NCT05378737 2026-01-06
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection
Bio-Thera Solutions
Phase 1 Completed
NCT05774873 2026-01-06
The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Completed
NCT05864573 2026-01-05
Study of ZGGS15 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Completed
NCT05240898 2025-12-18
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT05287399 2025-12-18
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
Ascletis Pharma Inc
Phase 1 Completed
NCT05105971 2025-12-08
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China
Bio-Thera Solutions
Phase 1 Completed
NCT05134948 2025-12-03
RELATIVITY 059
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04362748 2025-10-07
Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT04446260 2025-09-15
A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT05063318 2025-09-02
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT05494918 2025-08-22
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
Alphamab (Australia) Co Pty Ltd.
Phase 1 Completed
NCT05685472 2025-08-08
MEDI5752 in Japanese Patients With Advanced Solid Tumors.
AstraZeneca
Phase 1 Completed
NCT03853109 2025-07-20
AMG 404 in Patients With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT05487235 2025-07-03
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT05625412 2025-06-13
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT06381050 2025-06-13
The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Completed
NCT04393298 2025-05-29
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
UCB Pharma
Phase 1/2 Completed
NCT00529438 2025-05-28
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
Biogen
Phase 1 Completed
NCT04972981 2025-05-22
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
Phase 1 Completed
NCT03544905 2025-04-22
Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33
Haihe Biopharma Co., Ltd.
Phase 1 Completed
NCT04716634 2025-03-25
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT04882917 2025-03-07
First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
EMD Serono
Phase 1 Completed
NCT06012708 2025-01-08
Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713
New Cancer Cure-Bio Co.,Ltd.
Phase 1 Completed
NCT04052971 2025-01-06
To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation
Abion Inc
Phase 1 Completed
NCT04727554 2025-01-06
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT02057380 2024-11-20
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Astellas Pharma Inc
Phase 2 Completed
NCT02456883 2024-11-05
Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Completed
NCT03666143 2024-11-04
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
Phase 1 Completed
NCT04068519 2024-10-26
Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
BeiGene
Phase 1/2 Completed
NCT02516813 2024-10-15
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
EMD Serono
Phase 1 Completed
NCT03744403 2024-09-19
A Study of CS1001 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Completed
NCT04087018 2024-09-19
Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
Arcus Biosciences, Inc.
Phase 1 Completed
NCT01867866 2024-09-05
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
Taiho Oncology, Inc.
Phase 1 Completed
NCT02031055 2024-09-05
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1 Completed
NCT02454062 2024-09-04
A Trial of TAS-114 in Combination With S-1
Taiho Oncology, Inc.
Phase 1 Completed
NCT06172309 2024-07-29
A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 1 Completed
NCT04856774 2024-06-27
Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT05731934 2024-06-18
The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase 1 Completed
NCT05905614 2024-06-17
Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2 Completed
NCT02261285 2024-05-06
ONO-4538 Phase I Study in Patients With Solid Tumor
Ono Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02261298 2024-05-03
ONO-4538 Phase I Study in Patients With Solid Tumor
Ono Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02301130 2024-04-25
Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT05498480 2024-02-20
RELATIVITY-111
Bristol-Myers Squibb
Phase 1 Completed
NCT04921878 2024-02-09
A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Completed